AstraZeneca has appointed BioCity Nottingham to establish a new bioscience hub at its Alderley Park R&D site in Cheshire.
The BioHub will provide high-quality laboratory and office facilities for small pharma and biotech firms involved in drug discovery and development.
The ‘hub’ model of bioscience R&D has already achieved great success in Nottingham, Cambridge, Abingdon and Glasgow, providing benefits to tenant companies, investors and the regional economy.
The first three client companies – Blueberry Therapeutics Ltd, Imagen Biotech Ltd and Redx Anti-Infectives Ltd (a subsidiary of Redx Pharma) have already moved onto the site.
A total of 36,000 square feet of innovation space is available at the BioHub, and tenant companies expect to achieve rapid growth.
The BioCity management team has established hubs in Nottingham and Newhouse, just outside Glasgow.
AstraZeneca is providing the BioHub laboratories and offices, as well as access to restaurants, meeting rooms and conference facilities and to technical equipment.
Dr Glenn Crocker (pictured), CEO of BioCity Nottingham, said: “We are delighted to have been chosen to advise and help establish the BioHub at Alderley Park. We bring many years of experience in developing thriving communities of successful life science companies, and look forward to working closely with the AstraZeneca management team.
“We now have a unique opportunity to build connections between tenant companies based at Alderley Park, Nottingham and Scotland, which could ultimately transform the way life science innovation is achieved.”
While the closure of AstraZeneca’s R&D facility at the Alderley Park site (formerly owned by ICI) caused much concern within the industry, the BioHub plan ensures that the classic site will continue to host pharmaceutical innovation.